EVENTS · CRL
PEERS
EARNINGS
Charles River Laboratories International, Inc. is a life sciences company that provides products and services supporting pharmaceutical and biotechnology research, drug discovery, non-clinical development, and safety assessment. Its Research Models and Services business supplies purpose-bred rodents and genetically defined research models, along with related services used in laboratory and preclinical studies. Through Discovery and Safety Assessment, the company conducts regulated and non-regulated in vitro, in vivo, and in silico studies, laboratory support, consulting, and program management for potential medicines. Its Manufacturing Solutions activities include microbial testing and biologics-related services that help address quality, contamination control, and development requirements. Charles River Laboratories International, Inc. serves pharmaceutical and biotechnology companies, government agencies, academic institutions, and other research organizations across international life sciences markets. Its integrated role connects early laboratory research with the testing and development processes required to advance medical products toward regulatory review.
Charles River Laboratories dropped after it released third quarter results that disappointed investors
| Series | 1W | 1M |
|---|---|---|
| CRL | −12.8% | +7.0% |
| Peers | −1.0% | +9.5% |
| Sector · Health Care | +5.6% | +13.5% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 8 | 44 |
| QUARTER | EPS EST | EPS ACTUAL | EPS SURPRISE | REACTION |
|---|---|---|---|---|
| Q3 FY2026 | 2.98 | 3.09 | +3.69% | — |
| Q2 FY2026 | — | — | — | +13.41% |
| Q1 FY2026 | 1.96 | 2.06 | +4.98% | — |
| Q4 FY2025 | 2.37 | 2.39 | +0.98% | — |
| Q3 FY2025 | 2.36 | 2.43 | +2.88% | — |
| Series | 1W | 1M |
|---|---|---|
| CRL | −12.8% | +7.0% |
| Peers | −1.0% | +9.5% |
| Sector · Health Care | +5.6% | +13.5% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 8 | 44 |
